Alzheimer’s and Down Syndrome Vaccine Candidate Advances

A clinical-stage biopharmaceutical company announced 2 clinical milestones related to ACI-24, an anti-Abeta vaccine candidate against Alzheimer's disease and the Abeta-related cognitive decline in Down Syndrome.

ACI-24 is a liposomal therapeutic anti-Abeta vaccine candidate, which generates antibodies specific to disease-causing conformations. 

The vaccine is designed by AC Immune to stimulate a patient's immune system to produce antibodies that specifically target the oligomeric and fibrillary Abeta proteins, to prevent plaque accumulation and to enhance plaque clearance.

Andrea Pfeifer, the CEO of AC Immune, said in a press release, "We are delighted with the progress of ACI-24, which is currently the only clinical-stage vaccine targeting the associated Abeta-induced cognitive decline in people with Down Syndrome.”

“Vaccines are potentially an important option for the treatment and prevention of neurodegenerative diseases."

Comments

Popular posts from this blog

There is mounting evidence that herpes leads to Alzheimers Disease

Alzheimers 2018

15 Things That Slow Down Alzheimer’s Disease